Drug Channels

JULY 23, 2024

It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. These data remain inconvenient for drug pricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2023.

Drug Pricing 52

Drug Pricing Pharmaceutical Manufacturing Biosimilars 52

pharmaphorum

MARCH 10, 2022

It will also enter a five-year corporate integrity agreement (CIA) that contains unique drug price transparency and monitoring provisions focused on Medicaid and patient assistance programme activities.

Drug Pricing 105

Drug Pricing Pharmaceutical Manufacturing 105

Drug Channels

AUGUST 11, 2020

Time for our annual update on pricing at five of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, drug prices declined—or grew slowly—in 2019. d/b/a Drug Channels Institute. You can find links to each company’s data below.

Drug Pricing 52

Drug Pricing Pharmaceutical Manufacturing 52

Pharmaceutical Technology

NOVEMBER 21, 2022

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

Pharmaceutical Commerce

JUNE 17, 2025

A Further Examination of Pharmacy Benefit Managers Nicholas Saraceno, Editor March 29th 2024 Podcast Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Pharmaceutical Manufacturing 59

Drug Channels

MAY 20, 2025

Topics will include: The competitive landscape of retail pharmacy , with exclusive market data from DCI and 46brooklyn Key economic trends among leading PBMs and their impact on the market PBMs controversial effect on pharmacy and how theyre shaping the industry The medications driving pharmacy profits and the ones bringing financial pain The benefits (..)

Drug Pricing 75

Drug Pricing Pharmaceutical Manufacturing Hospitals 75

Drug Channels

MARCH 15, 2022

drug pricing, reimbursement, and dispensing system. The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. The chart below illustrates the depth and breadth of the 2022 edition.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Pharmaceutical Manufacturing Documentation 98

Drug Channels

APRIL 13, 2021

Time for Drug Channels ' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2020.

Drug Pricing 40

Drug Pricing Pharmaceutical Manufacturing 40

Drug Channels

JUNE 25, 2021

Time for Drug Channels ' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2020.

Drug Pricing 40

Drug Pricing Pharmaceutical Manufacturing 40

Pharmaceutical Technology

NOVEMBER 21, 2022

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

FDA Law Blog: Biosimilars

AUGUST 14, 2024

Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceutical manufacturers.

Drug Pricing 59

Drug Pricing Pharmaceutical Manufacturing 59

Proxsys Rx

APRIL 1, 2025

billion annually because of these restrictions, as drug companies limit 340B discounts on medications purchased through contract pharmacies. billion in 340B savings is at risk, due to increasing limitations imposed by pharmaceutical manufacturers which could further strain the healthcare safety net and patient care services.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Documentation Drug Pricing 52

Drug Channels

MARCH 18, 2025

Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! drug pricing, reimbursement, and dispensing system. prescription drug channels. What's inside?

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Pharmaceutical Manufacturing Hospitals 52

European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.

Biosimilars 52

Biosimilars Drug Pricing Pharmaceutical Manufacturing Pharmaceutical Companies 52

Pharmaceutical Commerce

JUNE 17, 2025

AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drug prices based on real-world patient outcomes.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

FDA Law Blog: Biosimilars

APRIL 16, 2024

Vanda Pharmaceuticals, Inc. Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. Centers for Medicare and Medicaid Servs., 23-1457 (4th Cir.

Dosage 59

Dosage Drug Pricing Pharmaceutical Manufacturing 59

Proxsys Rx

OCTOBER 6, 2022

That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package. And that reason has to be defensible, if it’s challenged in audit.

Hospitals 52

Hospitals Drug Pricing Communication Pharmaceutical Manufacturing 52

FDA Law Blog: Biosimilars

OCTOBER 4, 2023

By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare Drug Price Negotiation Program. Standing The Defendants questioned, and the court reviewed, Plaintiffs’ standing.

Drug Pricing 59

Drug Pricing Pharmaceutical Manufacturing Immunity Immunization 59

Proxsys Rx

JANUARY 10, 2023

Nobody’s ever put it better than the Association of American Medical Colleges (AAMC): “Congress created the 340B Drug Pricing Program in 1992 to protect safety-net hospitals from escalating drug prices by allowing them to purchase outpatient drugs at a discount from manufacturers.

Hospitals 52

Hospitals Drug Pricing Pharmaceutical Manufacturing Pharmaceutical Companies 52

Viseven

JANUARY 13, 2023

So, at the end of the day, the HEOR’s major task is to make sure that the patients who get access to the new treatment will get the best health outcomes at the most affordable price. HEOR Impact on Drug Pricing and Marketing. Naturally, HEOR experts take part in the pre-dev stages and assess the process at all following stages.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Dosage Drug Pricing 40

STAT

AUGUST 24, 2023

  A new analysis of mid-year price hikes has found that, despite policy changes under the Inflation Reduction Act, drug prices are on the rise , STAT reports. Biden health officials are expected to reveal the initial list before the stock market opens Tuesday morning.

Drug Pricing 246

Drug Pricing Pharmaceutical Manufacturing Drug Development 246

Pharmaceutical Commerce

JUNE 18, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Pharmacy Technician Pharmaceutical Companies 52

Pharmaceutical Commerce

JUNE 18, 2025

June 18th 2025 Article The June issue of Pharmaceutical Commerce highlights the importance of embracing agility—and adaptable strategies—to better navigate industry challenges.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Specialty Pharmacies Drug Pricing Pharmaceutical Manufacturing 52

Pharmaceutical Commerce

JUNE 16, 2025

Final thoughts Budget cuts may be coming, driven by drug pricing changes or economic pressures. Build in the ability to track key metrics such as time to therapy, abandonment rates, and financial impact of hub performance. Be ready to defend your hub by showing how it directly improves prescription lift, fills, and patient adherence.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Commerce

JUNE 18, 2025

How the Rise in Self-Injectables Is Impacting Pharmaceutical Manufacturing. Pharmaceutical Commerce. TekniPlex Healthcare Opens New Flagship Barrier Protection Systems Facility in Madison, Wisconsin. June 12, 2025. Accessed June 18, 2025. Robinson S. May 6, 2025. Accessed June 18, 2025. February 18, 2025.

Drug Pricing 52

Drug Pricing Packaging Pharmaceutical Companies Pharmaceutical Companies 52

Viseven

MAY 9, 2025

Role of HEOR in Pharmaceutical Industry With budget constraints tightening and drug prices facing greater scrutiny, Health Economics and Outcomes Research has become a cornerstone of modern pharmaceutical strategy. Drug pricing continues to dominate global discussions, ranking as the second major trend.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

Pharmaceutical Commerce

JUNE 13, 2025

Bill Roth Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry's ability to raise drug prices year after year—enabled by loopholes in PBM contracts—rather than high launch prices alone.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Drug Pricing Pharmaceutical Manufacturing Biosimilars 52

Pharmacy Times

JUNE 23, 2025

This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs. It is basically an essential copy, and the pharmaceutical manufacturer has to show bioequivalence to the reference product,” Soefje said. “If

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Pharmaceutical Commerce

JUNE 17, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Coverage and Processing Hospitals Drug Pricing 52

Pharmaceutical Commerce

JUNE 18, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Drug Pricing 52

Drug Pricing Specialty Pharmacies Pharmaceutical Manufacturing Documentation 52

Putting Patients First Blog

MAY 6, 2025

4 ,5 Millions of Americans rely on medicines that are manufactured outside the United States, particularly from close and longstanding allies such as Ireland, Switzerland, and the United Kingdomcountries whose regulatory frameworks for pharmaceutical manufacturing mirror the high standards enforced domestically.

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Generic Medicine Drug Pricing Hospitals 52

European Pharmaceutical Review

FEBRUARY 20, 2025

Impact on drug pricing and affordability Increased API costs may force some manufacturers to reduce output or exit the market entirely, reducing competition and potentially driving price inflation” Rising production costs due to tariffs could lead to higher drug prices, particularly in markets where pricing pressures are already a concern.

Drug Pricing 20

Drug Pricing Pharmaceutical Manufacturing Generic Medicine Hospitals 20

BioPharma Dive

JUNE 5, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

Drug Pricing 52

Drug Pricing Drug Development Vaccines Pharmaceutical Manufacturing 52

FDA Law Blog: Biosimilars

MAY 13, 2025

Wasserstein We are still parsing through the May 12 Executive Order (EO), Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients and impacts this may have on the pharmaceutical industry. Of interest to these bloggers is the provision that deals with personal use importation. (We Please bear with us.)

Online Pharmacies 59

Online Pharmacies Drug Pricing Documentation Pharmaceutical Manufacturing 59

Big Molecule Watch

MAY 15, 2025

14273 (EO 273), titled Lowering Drug Prices By Once Again Putting Americans First. Then, on May 12, 2025, President Trump signed an executive order titled Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients (the MFN EO). On April 15, 2025, President Trump signed Executive Order No.

Drug Pricing 59

Drug Pricing Biosimilars Pharmaceutical Manufacturing 59

STAT

MAY 20, 2025

The Trump administration shared on Tuesday the outlines of how it plans to push pharmaceutical companies to lower their U.S. drug prices to bring them more in line with other nations, kicking off high-stakes negotiations with the companies. Kennedy Jr. said in a statement. Continue to STAT+ to read the full story…

Drug Pricing 317

Drug Pricing Pharmaceutical Manufacturing Biosimilars Pharmaceutical Companies 317

STAT

MAY 15, 2025

… Roche warned that President Trump’s executive order on drug pricing threatens its planned $50 billion investment in the United States , Reuters writes. The order directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations. Best of luck, everyone.

Drug Pricing 170

Drug Pricing Pharmaceutical Manufacturing Vaccines 170